| Therapeutic | Efalizumab |
| Target | ITGAL |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK |
| 100% seqID Fv Structure | 3eo9 [Fvs: HL], 3eoa [Fvs: BA, HL], 3eob [Fvs: BA, HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3eo9 [Fvs: HL] |
| 100% seqID Structure | 3eoa [Fvs: BA, HL] |
| 100% seqID Structure | 3eob [Fvs: BA, HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | NFD |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2001 |
| INN Year Recommended | 2002 |
| Companies Involved | Genentech, Merck Serono, XOMA |
| Conditions Approved | Psoriasis |
| Conditions Active | na |
| Conditions Discontinued | Psoriatic arthritis, Type 1 diabetes mellitus |
| Notes |
